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Hormone replacement therapy (HRT) is frequently prescribed to healthy women to
ameliorate menopausal symptoms. HRT is used long term (≥ 1 year) to prevent chronic disease
in older women. The objective of this study was to review the benefits and risks of HRT
and studies of menopause or HRT in Taiwan via a MEDLINE search. Recommendations are
provided for future HRT research in Taiwan. Randomized, double-blind, placebo-controlled
clinical trials are considered the gold standard of scientific evidence. A MEDLINE literature
search (January 1966–July 2002) identified 23 papers on trials (≥ 1 year) that met the inclusion
criteria. The results showed that various HRT regimens used for more than 1 year caused
more harm than good in healthy menopausal women and that there was no benefit for women
with coronary artery disease, Alzheimer’s disease, hysterectomy, hysterosalpingo-
oophorectomy, and ischemic stroke. None of this research was conducted in Taiwan. A
MEDLINE search using the key words “estrogen replacement therapy and menopause in
Taiwan” identified 16 studies. There was only one, short-term, HRT trial. No evidence
suggested benefits from long-term HRT in menopausal women in Taiwan.
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Hormone replacement therapy (HRT) is frequently
prescribed to healthy women as a preventative
measure. Short-term (< 1 year) HRT use to ameliorate
menopausal symptoms has been reported [1]. Healthy
women also take long-term HRT with the purpose of
preserving their health and to prevent disease [2].
On July 9, 2002, the National Heart, Lung, and
Blood Institute of the US National Institutes of Health
(NIH) announced that it had stopped a trial of estrogen-
progestin versus placebo in healthy menopausal
women [3]. The trial was one component of the
Women’s Health Initiative (WHI). In the part of the
WHI study that was stopped, 16,608 postmenopausal
women aged 50 to 79 years received one tablet of
conjugated equine estrogens (CEE, 0.625 mg) plus
medroxyprogesterone (MPA, 2.5 mg) or placebo. The
trial was stopped after a mean of 5.2 years (planned
follow-up, 8.5 years) because the risks outweighed the
benefits. The WHI writing group cautioned that the
combination used in the trial should not be initiated or
continued. This step reveals the conscientiousness and
integrity of the researchers.
© 2003 Elsevier. All rights reserved.
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The number of studies relating to menopause have
increased in the past decade in Taiwan. However, the
response of the medical profession in Taiwan, primarily
that of gynecologists, to the results of the WHI trial has
generally been defensive, with continued insistence
on the effectiveness of HRT. Medical professionals
argued in the media that the absolute excess risks per
10,000 person-years in the WHI trial were too low to
cause concern (Liberty Times 2002/7/13), and because
the trial used one drug regimen only, it is doubtful
whether the results can be applied to other lower
dosages of these drugs or other formulations (United
Daily News 2002/7/12; Liberty Times 2002/7/14).
The objective of this study was to provide evidence
gathered from HRT research conducted outside Taiwan
and to offer recommendations for future HRT research
directions in Taiwan. Randomized, double-blind,
placebo-controlled trials are considered the most
comprehensive methods of  investigating the
effectiveness of a drug in most epidemiologic or public
health studies. The approval of a drug for clinical use
by the US Food and Drug Administration (FDA) largely
depends on the results of these trials [4]. Thus, the
authors selected randomized, double-blind, placebo-
controlled HRT trials (≥ 1 year duration) through a
MEDLINE search and reviewed the benefits and risks
of HRT use in menopausal women.
METHOD
Data sources were selected from studies with English-
language abstracts identified by a computerized
MEDLINE search (January 1966–July 2002) using the
key words estrogen replacement therapy, double-
blind, clinical trials, and random allocation. Only long-
term trials, in which participants had been randomized
to at least 1 year of therapy, were included.
RESULTS
Twenty-three papers on long-term (≥1 year) clinical
trials from important journals of medicine and
menopause met the inclusion criteria (Table 1). The
samples were selected from healthy women and
women with hysterectomy, hysterosalpingo-
oophorectomy, coronary artery disease, Alzheimer’s
disease, or ischemic stroke. Most trials were conducted
in the USA [3,5–20], with the remainder in Holland
[21,22], Denmark [23,24], Australia [25], and Italy [26];
there were none conducted in Taiwan. Only 16 studies
conducted in Taiwan, with English-language abstracts,
were identified in a similar MEDLINE search using
the key words estrogen replacement therapy and
menopause [27–42] (Table 2).
Table 1. Number of papers on long-term (≥ 1 year) hormone replacement therapy clinical trials in MEDLINE journals
Journal 1966–2002, abstract, English* + key words† Clinical trials ≥ 1 year RCT
JAMA 9,099 13 9 9
Maturitas 1,215 36 9 5
Am J Obstet Gynecol 14,340 23 5 3
N Engl J Med 6,569 6 3 3
Climacteric 120 12 3 1
Menopause 205 16 2 1
Arch Intern Med 7,499 7 1 1
BJOG‡ 164 1 1 0
Arch Gynecol Obstet 691 0 0 0
Psychosom Med 1,542 0 0 0
Am J Cardiol 13,958 5 0 0
J Nat Cancer Inst 6,945 2 0 0
Lancet 12,448 7 0 0
BMJ 6,166 2 0 0
Int J Cancer 10,908 0 0 0
Total 33 23
*Excluding review articles; †combined with key words (n = 452): estrogen replacement therapy, double-blind, clinical trials, random allocation, 1966–
2002, abstract, English; ‡BJOG: an international journal of obstetrics and gynecology. RCT = randomized, double-blind, placebo-controlled trial.
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Randomized, double-blind,
placebo-controlled trials (≥ 1 year)
Of the 23 studies, nine were part of long-term trials (3–
13 years) [3,5–10,14,15] and 13 were multicenter studies
[3,5–10,14–18,20].
For healthy women using estrogen (CEE 1.25,
0.625, 0.45, or 0.3 mg) or estrogen plus progesterone
(CEE 0.625, 0.45, or 0.3 mg plus MPA 10, 2.5, or 1.5 mg),
six papers reported that risks exceeded benefits and
five reported benefits only (Table 3).
The risks of long-term estrogen or estrogen plus
progesterone therapy (5.2 or 3 years) in healthy
menopausal women were: an increase in coronary
heart disease, stroke, pulmonary embolism, breast
cancer [3], and mean triglyceride levels [8] and
enhanced development of endometrial hyperplasia
[9]. The benefits of long-term HRT use (1 to 5.2 years)
in healthy menopausal women were: a decrease in the
risk of colorectal cancer and hip fracture [3], an increase
in bone mineral density [7,10,12], bone mineral content
[10], and postcranial and oral bone mass [11], a slowing
of bone loss [14],  and decreases in the mean
concentration of low-density lipoprotein cholesterol
[6,8] and the risk of forgetfulness [5].
Benefits of long-term HRT use (3 years) in women
with coronary artery disease were found in women
with flushing, but there were risks in women without
flushing [14]. Women with flushing who were assigned
to HRT had improved mental health and fewer
depressive symptoms during follow-up compared
with those assigned to placebo. Women without
flushing who were assigned to HRT had greater
declines in physical function and energy/fatigue
during follow-up (Table 4).
Among women with coronary artery disease,
Alzheimer’s disease and hysterectomy, three trials
reported that long-term HRT (1 to 4 years) had no
benefit in slowing the progression of Alzheimer’s
disease [15], in global cognitive or functional outcomes
[15], and in the reduction of the overall rate of coronary
heart disease [16,17] (Table 4).
Some trials with other HRT regimens were
conducted in Europe as the particular hormone
replacement combination investigated in the WHI is
not available there (Table 5).
Among healthy women using various HRT regimens
for 2 years, benefits were found with continuous
norethindrone acetate-ethinyl estradiol (NA-EE2)
combinations, 17 beta-estradiol, sequential estradiol/
norethisterone acetate (E2/NETA) combinations, and
continuous E2/NETA or E2/cyproterone acetate
combinations: increased bone mineral density [18],
bone loss prevention [19], and climacteric symptom
relief [23,24]. No benefit was found with tibolone [22].
When women with hysterectomy, hysterosalpingo-
oophorectomy, and ischemic stroke or transient
ischemic attack used raloxifene, 17 beta-estradiol, and
transdermal estradiol (1 to 2.8 years), no benefit was
found in the systolic function of the left ventricle [21],
in reducing the recurrence of stroke [20], and in
modifying atrioventricular conduction and ventricular
repolarization [26].
HRT and menopause research in Taiwan
We found 16 studies reporting on HRT and the
menopause in Taiwan (Tables 6 and 7). They covered:
the perception of menopausal women toward
menopause [27,37]; the risk of osteoporosis [29], high-
Table 2. Menopause or hormone replacement therapy (HRT) research conducted in Asian countries in MEDLINE
journals (1966–2002)
Country A: Research done in Asia Combined A with key words*
Taiwan 5,876 16
Japan 52,693 37
China 23,291 15
Korea 5,373 6
Malaysia 5,163 2
Singapore 4,722 5
Philippines 4,369 1
Total 82
*Combined key words (n = 20,672): estrogen replacement therapy (ERT) and menopause; excluding review articles.
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DISCUSSION
This paper reviewed 23 reports on randomized, double-
blind, placebo-controlled HRT trials (≥ 1 year duration)
identified from a MEDLINE search of abstracts from
January 1966 to July 2002. The results indicated that
various HRT regimens used for more than 1 year
caused more harm than good in healthy menopausal
women, and that they had no benefit in women with
coronary artery disease, Alzheimer’s disease,
hysterectomy, hysterosalpingo-oophorectomy, and
ischemic stroke or transient ischemic attack. Large-
scale epidemiologic research, such as cross-sectional
and cohort studies, frequently form the basis of public
health research. However, randomized, double-blind,
Table 4. Effects of hormone replacement therapy (HRT) in women with infirmity in randomized, double-blind,
placebo-controlled trials: conjugated equine estrogens (CEE)/medroxyprogesterone acetate (MPA) therapy
Author/location Follow- Subjects
up (yr)
Hlatky et al [14], 3 2,763 (< 80 y.o.)
USA: 20 centers with CAD:
HRT 1,380,
placebo 1,383
Mulnard et al [15], 1.25 120 with AD and
USA: 32 centers hysterectomy:
42 and 39 received
estrogen, 39 placebo
Herrington et al [16], 2 309 (49–80 y.o.,
USA: 6 centers mean 66) with
angiographically
verified coronary
disease: HRT 100,
104, placebo 105
Hulley et al [17], 4 2,763 (mean 67 y.o.)
USA: 20 centers with coronary
disease and intact
uterus: HRT 1,380,
placebo 1,383
*Women with flushing who were assigned to HRT had improved mental health and fewer depressive symptoms over follow-up compared
with those assigned to placebo. Women without flushing who were assigned to HRT had greater declines in physical function and energy/
fatigue over follow-up. CAD = coronary artery disease; AD = Alzheimer’s disease; CHD = coronary heart disease.
Main results
Risks exceed benefits
Benefits for women with
flushing, risks for women
without flushing*
No benefits
Estrogen did not slow disease
progression, and did not
improve global, cognitive, or
functional outcomes
No cardiovascular benefit
Treatment did not reduce
overall rate of CHD
Treatments
(HRT dose, mg/d)
CEE 0.625/MPA 2.5
CEE 0.625 or 1.25
CEE 0.625,
CEE 0.625/MPA 2.5
CEE 0.625/MPA 2.5
density lipoprotein cholesterol concentrations [31],
and breast cancer factors [35,36,38] in menopausal
women; increases in total cholesterol, low-density
lipoprotein cholesterol, triglycerides, apoprotein B
[28,32] and body fat [33,34]; age at menopause [30,40]
and menopausal symptoms [30,39,41]; and the
effectiveness of estrogen treatment for menopausal
women [42].
Only one study was a short-term HRT trial [42].
Most of the studies were conducted in Taipei [28,30–
32,35,36,38–42]. The studies included questionnaire
surveys, case-control studies, clinical studies, interview-
based studies, cross-sectional studies, and cohort
studies [28,32]. No evidence suggested long-term benefits
from HRT among menopausal women in Taiwan.
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Authors Institution(s)
Pan et al [27] Department of Obstetrics and Gynecology,
National Cheng-Kung University Hospital,
Tainan
Torng et al [28] Department of Obstetrics and Gynecology,
National Taiwan University College of
Medicine, Taipei
Chen et al [29] Department of Obstetrics and Gynecology,
School of Medicine, China Medical College
Hospital, Taichung
Fuh et al [30] The Neurological Institute, Taipei Veterans
General Hospital
Lyu et al [31] Graduate Program of Nutrition, National
Taiwan Normal University, Taipei
Torng et al [32] Department of Obstetrics and Gynecology,
National Taiwan University College of
Medicine, Taipei
Chang et al [33] Department of Family Medicine & Nuclear
Medicine, National Cheng Kung University
Hospital, Tainan
Tsai & Chou [34] Chang Gung Institute of Nursing, Taoyuan
Huang et al [35] Department of Surgery, College of
Medicine, National Taiwan University,
Taipei
Huang et al [36] Department of Surgery, National Taiwan
University Hospital, Taipei
Chen et al [37] Westminster College School of Nursing,
Salt Lake City, Utah, USA
Yang et al [38] Mackay Memorial Hospital, Academia
Sinica, Taipei
Chang & Chang [39] Institute of Health Policy & Management,
National Taiwan University, Taipei
Chang et al [40] Institute of Health Policy & Management,
and the Department of Obstetrics &
Gynecology, National Taiwan University,
Taipei
Lin et al [41] Department of Obstetrics and Gynecology,
College of Medicine, National Taiwan
University, Taipei
Ouyang et al [42] Department of Obstetrics and Gynecology,
College of Medicine and the Hospital,
National Taiwan University, Taipei
BMD = bone mineral density; CVD = cardiovascular disease.
Table 6. Hormone replacement therapy and menopause studies in Taiwan (in reverse chronological order)
Topic
Perception of menopause among women
in Taiwan
Effects of menopause on changes in serum
lipids, blood pressure and body weight
Relation of the estrogen receptor alpha
gene microsatellite polymorphism to BMD
and osteoporosis
Menopausal study of a population aged
40–54
Association of sex, adiposity, and diet
with high-density lipoprotein subclasses in
middle-aged Chinese
Effects of menopause and obesity on lipid
profiles in middle-aged Taiwanese women
Relationships of age, menopause, and
central obesity on CVD risk factors in
Chinese women
Association of body fat distribution with
lifestyle and reproductive factors
Cytochrome P4501A1 polymorphism as a
susceptibility factor for breast cancer
Association between N-acetyltransferase 2
genetic polymorphism and breast cancer
Chinese midlife women’s perceptions and
attitudes about menopause
Breast cancer in Taiwan
Experience of menopause and hormone
use in women in Taiwan
Age of menopause of women in Taiwan
Clinical study of postmenopausal bleeding
Total serum estrogen levels and urinary
excretion of calcium and hydroxyproline
in pre- and postmenopausal women
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Table 7. Hormone replacement therapy (HRT) and menopause studies in Taiwan
Authors Design Subjects (age range, yr)
Pan et al [27] Questionnaire 386 women
Chen et al [37] Questionnaire 168 women
Chen et al [29] BMD 174 women
measurement
Torng et al [28,32] Cohort 671 pre- and 872
study postmenopausal
women (45–54)
Lyu et al [31] Interviews 203 women, 206 men
Chang et al [33] Cross-sectional 136 pre- and 193
study postmenopausal women
Tsai & Chou [34] Cross-sectional 1,310 women (45–54)
study
Huang et al Case-control 150 breast cancer
[35,36] study patients, 150 controls
Yang et al [38] Case-control 244 breast cancer
study patients, 450 controls
Fuh et al [30] Questionnaire 1,497 women (40–54)
Chang & Questionnaire 673 women (40–60)
Chang [39]
Chang et al [40] Interviews 771 women (40–60)
Lin et al [41] Clinical study 381 postmenopausal
women with abnormal
vaginal bleeding
Ouyang et al [42] Premarin 14 natural, 14 surgical,
treatment (0.625 and 4 post-irradiation
or 1.25 mg/d) menopausal women
BMD = bone mineral density; TC = total cholesterol; LDL = low-density lipoprotein; TG = triglyceride; HDL = high-density lipoprotein.
Main results
Perception
97% have heard of the menopause; 53%
knew its definition; most common source of
knowledge was reading material (43%),
friends (22%); 71% thought they should
receive therapy
92% perceived menopause as natural; 41%
obtained menopause information from
friends and printed materials
Risk of osteoporosis
Estrogen receptor alpha gene microsatellite
polymorphism may be a candidate genetic
marker for risk of osteoporosis
Cholesterol
Menopause associated with increases in TC,
LDL-cholesterol, TG, and apoprotein B
levels
Women had higher concentrations of HDL-
cholesterol than men
Body fat
Through aging and menopausal effects,
women will have increased total body fat
content
Overall obesity and menopausal status are
determinants of body fat distribution
Breast cancer
N-acetyltransferase 2 polymorphism or
cytochrome P4501A1 polymorphism are
susceptibility factors for breast cancer in
women
Family history of breast cancer appears to
be the most important risk factor for breast
cancer
Age and symptoms
Age at menopause did not differ from
Western studies, but menopausal symptoms,
especially vasomotor symptoms, are much
lower than in the West
Discomfort low compared with Western
countries; most frequent discomforts:
backache/lumbago, amentia, tiredness
Mean menopausal age 49.8 ± 3.28 yr
(median 50, range 38–55)
55.6% had normal histologic findings, 21.9%
benign pathologic findings, 3.6% cervical
intraepithelial neoplasia, 11% endometrial
hyperplasia, 5% cervical cancer, 2.9%
endometrial cancer, and obesity correlated
with malignancy
Treatment
Premarin effectively treated menopausal
syndrome
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placebo-controlled trials are considered the most
comprehensive. The approval of a drug for clinical use
largely depends on the results of such trials [4]. As the
results are usually already convincing, further
statistical analyses such as meta-analyses are not
necessary to present additional credible scientific
evidence.
We found no randomized, double-blind, placebo-
controlled HRT trial (≥ 1 year) conducted in Taiwan.
Only one short-term HRT trial was published [42],
and there was no evidence to suggest long-term
benefits from HRT use.
The  t r ia l s  rev iewed in  th i s  paper  were
predominantly conducted in the USA and Europe;
none were conducted in Asia. Therefore, research into
the special coping strategies of menopausal women in
Asia is essential. Eighty-two studies with English-
language abstracts were selected from a computerized
MEDLINE search using the key words estrogen
replacement therapy and menopause in various Asian
countries (Table 2). The main themes reported were:
the occurrence of climacteric complaints or menopausal
symptoms and menopausal age [43–56]; the effects of
HRT treatment or compliance and the sale of estrogen
replacement products [57–68]; the perception of
menopause, depression, psychological distress, and
the effects of counseling on climacteric symptoms [69–
72]; the risk of Alzheimer’s disease, menopause-related
vascular  changes ,  bone loss ,  bone densi ty ,
contraceptive status and sexual function [73–102]; the
pattern of postmenopausal bleeding, the measurement
of normal ovaries and plasma lipid and lipoprotein
levels [103–105]; and special diets [106–108].
These Asian studies do not provide any additional
credible scientific evidence to that from the 23 reports
on randomized, double-blind, placebo-controlled HRT
trials conducted in the USA and Europe.
RECOMMENDATIONS
Three major propositions are recommended for future
research in Taiwan. First, the purpose of healthy
women taking long-term HRT is to preserve health
and prevent disease [2]. Freedman et al argue that a
single outcome is often not an appropriate paradigm
for trials of disease prevention but the interventions
often have potential effects on several diseases [109].
Thus, a major rationale for a trial may be to estimate all
of these effects more precisely, thereby providing a
basis for informed public health decisions [109]. Simply
repeating the WHI trial or other similar HRT research
with subjects in Taiwan is undesirable. It is more
appropriate to investigate the effects of HRT on a
wider range of diseases or disciplines. For instance,
breast cancer in Taiwan occurs in younger women
compared with the West. The question is whether the
increase in HRT use will cause a rise in the incidence of
breast cancer in Taiwan. This issue will require further
research. A multidisciplinary research team composed
of  medica l  exper t s ,  publ i c  hea l th  exper t s ,
epidemiologists, and statisticians to carry out this
research would be optimal.  Furthermore, the
experience of menopausal women, their health needs
and medical demands, and long-term follow-up of
women’s health are essential in Taiwan.
Second, the NIH in the USA, responding to the
demand of women’s organizations and congress-
women in 1991, initiated a large-scale estrogen-
progestin versus placebo trial in healthy menopausal
women [110]. However, there was little reaction from
the National Health Research Institutes in Taiwan
when the WHI study in the USA was stopped. Although
the Department of Health in Taiwan has posted
guidelines for HRT use on its website in response to
the halted WHI study, they do not provide information
on healthcare for menopausal women and alternatives
when women do not want to use medication. In Taiwan,
HRT resources offered to medical personnel and to the
media are distributed predominantly by the
pharmaceutical industry. To combat this, we propose
that the National Health Research Institutes in Taiwan
take responsibility for making HRT resources available.
With respect to the health of the general public, there
is a need for ethical management and responsibility
from related medical societies in combating the over-
marketing of medicines in the Taiwanese media.
Additional research is needed to tackle this situation.
Third, regarding the use of HRT, gynecologists’ or
allied physicians’ arguments over the different physical
constitutions of women in the East and West have been
increasing in Taiwan since the WHI trial was stopped.
Instead of singling out HRT use, research attention
should be focused on the effect of any type of
medication on different physical constitutions. This
kind of research is recommended to begin as soon as
possible in order to avoid any possible overdosage
side effects.
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